FDA grants NDA for intravitreal sirolimus for non-infectious uveitis of posterior segment

The FDA has accepted a new drug application for intravitreal sirolimus for the treatment of non-infectious uveitis of the posterior segment, Santen announced in a press release.An action date of Dec. 24 has been set for the completion of the NDA review, according to the release.